Antitrust Antitrust

Aspen Pharmacare poised to see EU wrap up drug-pricing probe

By Lewis Crofts and Arezki Yaïche
  • 09 Feb 2021 11:52
  • 09 Feb 2021 12:07
Aspen Pharmacare will see the end of an EU investigation into six cancer drugs as early as tomorrow with a legal promise to cut prices, MLex has learned.

The European Commission is expected to formalize Aspen’s concessions to curb its suspect conduct and close the probe without a fine.

In July, the

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News